Carlos Andrés Celis-Preciado
@pulmonology101.bsky.social
Pulmonologist, Fellow Airways Diseases | PhD (c) Immunology |PRISMA Lab, Université de Sherbrooke, Québec, Canada.
#asthma #COPD #bronchiectasis #biomarkers
#asthma #COPD #bronchiectasis #biomarkers
Pinned
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials
Blood eosinophil count, FeNO, asthma attack history, disease severity, low lung function
(low FEV1%), and symptoms (ACQ-5 score) are key predictors of asthma attacks. Conversely,
we found that moderat...
www.thelancet.com
🚨 Our new paper is out in The Lancet Respiratory Medicine!
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
Reposted by Carlos Andrés Celis-Preciado
Great response to our correspondence to Clarice Leung and John Fahy on the association between FeNO and baseline membrane thickness in SARP-3. This seems like a good marker of type-2 inflammation, and more specifically IL-13 activity, in #asthma.
www.atsjournals.org/doi/abs/10.1...
www.atsjournals.org/doi/abs/10.1...
July 4, 2025 at 12:21 PM
Great response to our correspondence to Clarice Leung and John Fahy on the association between FeNO and baseline membrane thickness in SARP-3. This seems like a good marker of type-2 inflammation, and more specifically IL-13 activity, in #asthma.
www.atsjournals.org/doi/abs/10.1...
www.atsjournals.org/doi/abs/10.1...
Reposted by Carlos Andrés Celis-Preciado
📰 For #WorldAsthmaDay check out this #OpenAccess meta-analysis on inflammatory and clinical risk factors for #asthma attacks (ORACLE2)
Findings support incorporation of blood eosinophils and FeNO into clinical risk stratification
🔗 tinyurl.com/93ar3am3
@simcouillard.bsky.social
Findings support incorporation of blood eosinophils and FeNO into clinical risk stratification
🔗 tinyurl.com/93ar3am3
@simcouillard.bsky.social
May 6, 2025 at 11:22 AM
📰 For #WorldAsthmaDay check out this #OpenAccess meta-analysis on inflammatory and clinical risk factors for #asthma attacks (ORACLE2)
Findings support incorporation of blood eosinophils and FeNO into clinical risk stratification
🔗 tinyurl.com/93ar3am3
@simcouillard.bsky.social
Findings support incorporation of blood eosinophils and FeNO into clinical risk stratification
🔗 tinyurl.com/93ar3am3
@simcouillard.bsky.social
Reposted by Carlos Andrés Celis-Preciado
"Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype."
Publié ce jour dans le @nejm.org.
#MedSky @simcouillard.bsky.social
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky @simcouillard.bsky.social
www.nejm.org/doi/full/10....
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype | NEJM
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...
www.nejm.org
May 1, 2025 at 11:00 AM
"Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype."
Publié ce jour dans le @nejm.org.
#MedSky @simcouillard.bsky.social
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky @simcouillard.bsky.social
www.nejm.org/doi/full/10....
Reposted by Carlos Andrés Celis-Preciado
In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU
#ATS2025 @atscommunity.bsky.social
#ATS2025 @atscommunity.bsky.social
May 18, 2025 at 9:20 PM
In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU
#ATS2025 @atscommunity.bsky.social
#ATS2025 @atscommunity.bsky.social
Reposted by Carlos Andrés Celis-Preciado
🧵A new COPD diagnostic schema that includes chest imaging, respiratory symptoms, and spirometry identified more high-risk individuals and excluded low-risk ones. #ATS2025
ja.ma/4dp9i30
ja.ma/4dp9i30
May 19, 2025 at 12:21 AM
🧵A new COPD diagnostic schema that includes chest imaging, respiratory symptoms, and spirometry identified more high-risk individuals and excluded low-risk ones. #ATS2025
ja.ma/4dp9i30
ja.ma/4dp9i30
Reposted by Carlos Andrés Celis-Preciado
Hey #ATS2025, help us spread the word on our revolutionary person-centered framework on supplemental oxygen to improve wellbeing & independence for patients & families.
jamanetwork.com/journals/jam...
@pallipulm.bsky.social
@atscommunity.bsky.social
@jamainternalmed.com
@angelasuen.bsky.social
jamanetwork.com/journals/jam...
@pallipulm.bsky.social
@atscommunity.bsky.social
@jamainternalmed.com
@angelasuen.bsky.social
May 19, 2025 at 8:01 PM
Hey #ATS2025, help us spread the word on our revolutionary person-centered framework on supplemental oxygen to improve wellbeing & independence for patients & families.
jamanetwork.com/journals/jam...
@pallipulm.bsky.social
@atscommunity.bsky.social
@jamainternalmed.com
@angelasuen.bsky.social
jamanetwork.com/journals/jam...
@pallipulm.bsky.social
@atscommunity.bsky.social
@jamainternalmed.com
@angelasuen.bsky.social
Reposted by Carlos Andrés Celis-Preciado
A JAMA study examines a multidimensional diagnostic approach for #COPD that uses a new diagnostic schema for more individualized and inclusive COPD patient care. #ATS2025
ja.ma/3GYcUg1
ja.ma/3GYcUg1
May 19, 2025 at 9:00 PM
A JAMA study examines a multidimensional diagnostic approach for #COPD that uses a new diagnostic schema for more individualized and inclusive COPD patient care. #ATS2025
ja.ma/3GYcUg1
ja.ma/3GYcUg1
Reposted by Carlos Andrés Celis-Preciado
Congrats to our teaching competition representative Dr. Chris Chou for winning the #ATS2025 teaching competition ✍️with his novel approach to explaining chest tube mechanics! 🫁
@ats-assemblies.bsky.social
@ats-assemblies.bsky.social
May 19, 2025 at 9:40 PM
Congrats to our teaching competition representative Dr. Chris Chou for winning the #ATS2025 teaching competition ✍️with his novel approach to explaining chest tube mechanics! 🫁
@ats-assemblies.bsky.social
@ats-assemblies.bsky.social
Reposted by Carlos Andrés Celis-Preciado
1/ The amazing UW PCCM fellows are headed to #ATS2025! 🤩
In these challenging times, their commitment to research and improving patient care gives me hope.
@atscommunity.bsky.social
@atsearlycareer.bsky.social
@apccmpd.bsky.social
In these challenging times, their commitment to research and improving patient care gives me hope.
@atscommunity.bsky.social
@atsearlycareer.bsky.social
@apccmpd.bsky.social
May 16, 2025 at 7:32 PM
1/ The amazing UW PCCM fellows are headed to #ATS2025! 🤩
In these challenging times, their commitment to research and improving patient care gives me hope.
@atscommunity.bsky.social
@atsearlycareer.bsky.social
@apccmpd.bsky.social
In these challenging times, their commitment to research and improving patient care gives me hope.
@atscommunity.bsky.social
@atsearlycareer.bsky.social
@apccmpd.bsky.social
Reposted by Carlos Andrés Celis-Preciado
🚨 Funded Clinical Research Fellowship
Asthma/COPD focus | MSc/PhD req | 2–3 yrs | 80% research, 20% clinic | Sherbrooke, QC 🇨🇦
French is a must (95% francophone patients).
📩 S.Couillard@USherbrooke.ca
🌐 DM for details!
www.usherbrooke.ca/dep-medecine...
Asthma/COPD focus | MSc/PhD req | 2–3 yrs | 80% research, 20% clinic | Sherbrooke, QC 🇨🇦
French is a must (95% francophone patients).
📩 S.Couillard@USherbrooke.ca
🌐 DM for details!
www.usherbrooke.ca/dep-medecine...
www.usherbrooke.ca
April 21, 2025 at 4:06 PM
🚨 Funded Clinical Research Fellowship
Asthma/COPD focus | MSc/PhD req | 2–3 yrs | 80% research, 20% clinic | Sherbrooke, QC 🇨🇦
French is a must (95% francophone patients).
📩 S.Couillard@USherbrooke.ca
🌐 DM for details!
www.usherbrooke.ca/dep-medecine...
Asthma/COPD focus | MSc/PhD req | 2–3 yrs | 80% research, 20% clinic | Sherbrooke, QC 🇨🇦
French is a must (95% francophone patients).
📩 S.Couillard@USherbrooke.ca
🌐 DM for details!
www.usherbrooke.ca/dep-medecine...
🚨 Our new paper is out in The Lancet Respiratory Medicine!
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials
Blood eosinophil count, FeNO, asthma attack history, disease severity, low lung function
(low FEV1%), and symptoms (ACQ-5 score) are key predictors of asthma attacks. Conversely,
we found that moderat...
www.thelancet.com
April 9, 2025 at 2:43 AM
🚨 Our new paper is out in The Lancet Respiratory Medicine!
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
ORACLE2 pooled 6,500+ #asthma patients from 22 RCTs.
🧪 Blood #eosinophils + #FeNO = key predictors of #asthma attacks
💨 Reversibility = lower risk?
Open access: www.thelancet.com/journals/lan...
#asthma #ORACLE2
Reposted by Carlos Andrés Celis-Preciado
🚨 New paper in @lancetrespirmed.bsky.social !
ORACLE2: we pooled data from 6,500+ asthma patients x22 RCTs.
🧪 Blood eosinophils + FeNO = powerful predictors of asthma attacks (esp. together)
💨 Surprise: more lung reversibility = lower risk?
Open access 👉 doi.org/10.1016/S221...
Global collab 💪
ORACLE2: we pooled data from 6,500+ asthma patients x22 RCTs.
🧪 Blood eosinophils + FeNO = powerful predictors of asthma attacks (esp. together)
💨 Surprise: more lung reversibility = lower risk?
Open access 👉 doi.org/10.1016/S221...
Global collab 💪
April 9, 2025 at 1:39 AM
🚨 New paper in @lancetrespirmed.bsky.social !
ORACLE2: we pooled data from 6,500+ asthma patients x22 RCTs.
🧪 Blood eosinophils + FeNO = powerful predictors of asthma attacks (esp. together)
💨 Surprise: more lung reversibility = lower risk?
Open access 👉 doi.org/10.1016/S221...
Global collab 💪
ORACLE2: we pooled data from 6,500+ asthma patients x22 RCTs.
🧪 Blood eosinophils + FeNO = powerful predictors of asthma attacks (esp. together)
💨 Surprise: more lung reversibility = lower risk?
Open access 👉 doi.org/10.1016/S221...
Global collab 💪
Reposted by Carlos Andrés Celis-Preciado
🚀 Exciting News! 🚀 Thrilled to share that our paper, Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA), has been accepted for publication in the European Respiratory Society ERJ journal! 🎉 Congratulations to 1st author @pulmonology101.bsky.social
Phenotyping Responses to Systemic Corticosteroids in the Management of #Asthma Attacks (PRISMA). Blood #eosinophils and #FeNO can stratify asthma #exacerbations, predicting better clinical responses to #OCS. @simcouillard.bsky.social @usherbrooke.bsky.social
publications.ersnet.org/content/erj/...
publications.ersnet.org/content/erj/...
February 20, 2025 at 2:14 PM
🚀 Exciting News! 🚀 Thrilled to share that our paper, Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA), has been accepted for publication in the European Respiratory Society ERJ journal! 🎉 Congratulations to 1st author @pulmonology101.bsky.social
Phenotyping Responses to Systemic Corticosteroids in the Management of #Asthma Attacks (PRISMA). Blood #eosinophils and #FeNO can stratify asthma #exacerbations, predicting better clinical responses to #OCS. @simcouillard.bsky.social @usherbrooke.bsky.social
publications.ersnet.org/content/erj/...
publications.ersnet.org/content/erj/...
February 19, 2025 at 11:30 PM
Phenotyping Responses to Systemic Corticosteroids in the Management of #Asthma Attacks (PRISMA). Blood #eosinophils and #FeNO can stratify asthma #exacerbations, predicting better clinical responses to #OCS. @simcouillard.bsky.social @usherbrooke.bsky.social
publications.ersnet.org/content/erj/...
publications.ersnet.org/content/erj/...
Reposted by Carlos Andrés Celis-Preciado
Apprenez en davantage sur notre projet Propulsion Santé 👉. Merci FMSQ pour le beau résumé et la visibilité. Merci AstraZeneca, Opération-Enfant-Soleil , et Association pulmonaire du Québec pour le financement ayant permis de partir un projet qui se déploie maintenant à vitesse grand V. 🚀
Le projet du Dr Simon Couillard, pneumologue, améliore le diagnostic et le traitement de l’asthme. Les innovations des médecins spécialistes sont indispensables à l’évolution de notre santé.
👉 Lisez des histoires inspirantes de médecins spécialistes québécois : fmsq.org/fr/objectif-...
#santeqc
👉 Lisez des histoires inspirantes de médecins spécialistes québécois : fmsq.org/fr/objectif-...
#santeqc
January 29, 2025 at 3:28 PM
Apprenez en davantage sur notre projet Propulsion Santé 👉. Merci FMSQ pour le beau résumé et la visibilité. Merci AstraZeneca, Opération-Enfant-Soleil , et Association pulmonaire du Québec pour le financement ayant permis de partir un projet qui se déploie maintenant à vitesse grand V. 🚀
Reposted by Carlos Andrés Celis-Preciado
Honored to step into the role of Director of the Public Health Institute at Javeriana University in Bogotá.
Grateful for the journey so far and eager to drive meaningful change in public health while strengthening collaboration across Latin America and beyond.
Grateful for the journey so far and eager to drive meaningful change in public health while strengthening collaboration across Latin America and beyond.
January 18, 2025 at 8:18 PM
Honored to step into the role of Director of the Public Health Institute at Javeriana University in Bogotá.
Grateful for the journey so far and eager to drive meaningful change in public health while strengthening collaboration across Latin America and beyond.
Grateful for the journey so far and eager to drive meaningful change in public health while strengthening collaboration across Latin America and beyond.
Reposted by Carlos Andrés Celis-Preciado
The @theguardian.com is now wondering whether Elon Musk made a "Nazi salute" or a "Roman salute" 🤦♀️
Picking up any secondary school history book would be sufficient to know there is pretty much no difference - Hitler copied Mussolini
Picking up any secondary school history book would be sufficient to know there is pretty much no difference - Hitler copied Mussolini
January 21, 2025 at 7:58 PM
The @theguardian.com is now wondering whether Elon Musk made a "Nazi salute" or a "Roman salute" 🤦♀️
Picking up any secondary school history book would be sufficient to know there is pretty much no difference - Hitler copied Mussolini
Picking up any secondary school history book would be sufficient to know there is pretty much no difference - Hitler copied Mussolini
Reposted by Carlos Andrés Celis-Preciado
This self-guided curriculum from University of Washington SOM provides a structured approach connecting key lung anatomy to patterns of disease & is an effective way to teach chest computed tomography interpretation to pulmonary fellows. www.mededportal.org/doi/10.15766... #MedEd #Medsky
A Structured, Anatomy-Based Chest CT Interpretation Curriculum for Pulmonary Fellows Covering the Main Patterns of Parenchymal Lung Disease | MedEdPORTAL
Introduction Chest computed tomography (CT) interpretation is a key competency for pulmonary fellows,
with many resources intended for radiologists but very few for this specific group.
We endeavored ...
www.mededportal.org
January 14, 2025 at 8:38 PM
This self-guided curriculum from University of Washington SOM provides a structured approach connecting key lung anatomy to patterns of disease & is an effective way to teach chest computed tomography interpretation to pulmonary fellows. www.mededportal.org/doi/10.15766... #MedEd #Medsky
Reposted by Carlos Andrés Celis-Preciado
@natmedicine.bsky.social is also now on Bluesky! 🎉
You can follow all of our journals with our starter pack.
You can follow all of our journals with our starter pack.
January 9, 2025 at 1:56 PM
@natmedicine.bsky.social is also now on Bluesky! 🎉
You can follow all of our journals with our starter pack.
You can follow all of our journals with our starter pack.
Reposted by Carlos Andrés Celis-Preciado
How eating fiber->short-chain fatty acid (SCFA) metabolites->anti-cancer effects
nature.com/articles/s42...
nature.com/articles/s42...
nature.com/articles/s42...
nature.com/articles/s42...
January 9, 2025 at 3:22 PM
How eating fiber->short-chain fatty acid (SCFA) metabolites->anti-cancer effects
nature.com/articles/s42...
nature.com/articles/s42...
nature.com/articles/s42...
nature.com/articles/s42...
Reposted by Carlos Andrés Celis-Preciado
"unlike type 1 immune responses, type 2 immunity is perceived as a potential promoter of tumorigenesis. Emerging evidence challenges this perspective, painting a more nuanced picture in which type 2 immunity might protect against or even actively suppress tumour growth and progression." #ImmunoSky
Reinventing type 2 immunity in cancer - Nature
This Review addresses the roles of type 2 immunity in cancer and the potential for cancer immunotherapies targeting this pathway.
www.nature.com
January 9, 2025 at 7:15 PM
"unlike type 1 immune responses, type 2 immunity is perceived as a potential promoter of tumorigenesis. Emerging evidence challenges this perspective, painting a more nuanced picture in which type 2 immunity might protect against or even actively suppress tumour growth and progression." #ImmunoSky
Reposted by Carlos Andrés Celis-Preciado
Grateful for the opportunity to briefly discuss the findings in our group’s @jama.com article on identifying asthma endotypes through nasal epithelial transcriptomic profiles with Dr Kristin Walter. @upmc.bsky.social @atscommunity.bsky.social
Certain CD4+ T-cell subtypes play a role in asthma, and characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma.
Author Juan Celedon discusses this and more with JAMA Deputy Editor Kristin Walter.
ja.ma/4gIGrHS
Author Juan Celedon discusses this and more with JAMA Deputy Editor Kristin Walter.
ja.ma/4gIGrHS
January 2, 2025 at 10:25 PM
Grateful for the opportunity to briefly discuss the findings in our group’s @jama.com article on identifying asthma endotypes through nasal epithelial transcriptomic profiles with Dr Kristin Walter. @upmc.bsky.social @atscommunity.bsky.social
Reposted by Carlos Andrés Celis-Preciado
Fascinating study on pediatric #asthma endotypes (full-text link @jama.com: ja.ma/402KbwE)
#Medsky #Pedsky #PedPulmSky
@ats-peds.bsky.social
#Medsky #Pedsky #PedPulmSky
@ats-peds.bsky.social
January 3, 2025 at 1:45 AM
Fascinating study on pediatric #asthma endotypes (full-text link @jama.com: ja.ma/402KbwE)
#Medsky #Pedsky #PedPulmSky
@ats-peds.bsky.social
#Medsky #Pedsky #PedPulmSky
@ats-peds.bsky.social
Reposted by Carlos Andrés Celis-Preciado
In this @jama.com article, Molin Yue+ Dr Kristina Gaietto show similar proportions of nasal epithelial transcriptomic profiles for T2-high, T17-high+ T2-low/T17-low asthma across 3 cohorts of predom. Puerto Rican+ Black youth, with T2-high less common than T2-low profiles. @atscommunity.bsky.social
🧵In 3 studies that included predominantly Puerto Rican and Black youths with #asthma, a nasal transcriptomic profile consistent with the T2HIGH profile was least common across all studies.
#MedSky
ja.ma/402KbwE
#MedSky
ja.ma/402KbwE
January 2, 2025 at 10:20 PM
In this @jama.com article, Molin Yue+ Dr Kristina Gaietto show similar proportions of nasal epithelial transcriptomic profiles for T2-high, T17-high+ T2-low/T17-low asthma across 3 cohorts of predom. Puerto Rican+ Black youth, with T2-high less common than T2-low profiles. @atscommunity.bsky.social